Drug studies financed by pharmaceutical companies frequently show positive results in favor of the sponsor. In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107(16): 279-85), a research group headed by the Chairman of the Drug Commission of the German Medical Association, Prof. Wolf-Dieter Ludwig, describes the influence of sponsoring on the results, protocol, and quality of drugs studies. Check the end of this report for a link to download this open access article.
The authors conclude that pharmaceutical companies exploit a wide variety of possibilities of manipulating study results. Apart from financing the study, financial links to the authors, such as payments for lectures, may tend to make the results of the study more favorable for the company. Not only the results themselves, but also their interpretation, are significantly more often in accordance with the wishes of the sponsor.
In some publications, the authors detected evidence that sponsors from the pharmaceutical industry had influenced study protocols. For example, placebos were more frequently used in drug studies than was the case with independently financed studies. On the other hand, some favorable effects were linked to financial support from the pharmaceutical industry. The methodological quality of studies with industrial support tended to be better than with independent drug studies.
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K (2010). The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences: Part 1. A Qualitative, Systematic Review of the Literature on Possible Influences on the Findings, Protocols, and Quality of Drug Trials. Dtsch Arztebl Int, 107(16), 279-85.